{"id":139109,"title":"AstraZeneca Loses £15 Billion in Value on Bristol Myers Squibb Merger Report","publisher":"Share Talk","author":"sharetalk","published":"2026-08-03T08:13:32+00:00","modified":"2026-08-03T08:16:02+00:00","canonical_url":"https://www.share-talk.com/astrazeneca-loses-15-billion-in-value-on-bristol-myers-squibb-merger-report/","markdown_url":"https://www.share-talk.com/astrazeneca-loses-15-billion-in-value-on-bristol-myers-squibb-merger-report.md","json_url":"https://www.share-talk.com/astrazeneca-loses-15-billion-in-value-on-bristol-myers-squibb-merger-report.json","category":"Health","categories":["Health","Healthcare","Pharmaceutical"],"tags":["AstraZeneca","Bristol-Myers Squibb","Cambridge","Macclesfield","Pfizer"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/08/AstraZeneca-3-AUG-26.jpg?fit=2384%2C1257&quality=89&ssl=1","format":"news","language":"en-GB","content":"More than **£15 billion** was wiped from AstraZeneca’s market value on Monday after reports that the pharmaceutical group has held talks over a potential **US$400 billion merger** with US rival **Bristol Myers Squibb**.\n\nAstraZeneca shares fell **7.6%** to their lowest level since October as investors reacted to the prospect of one of the largest corporate combinations ever attempted.\n\nThe Cambridge-based drugmaker is currently valued at around **£184 billion**, while New York-listed Bristol Myers Squibb has a market capitalisation of approximately **US$133 billion**.\n\nA completed deal would create one of the world’s largest pharmaceutical companies, but it would also raise fresh questions over AstraZeneca’s long-term ties to the UK.\n\nChief executive **Pascal Soriot** has increasingly expanded the group’s US presence. AstraZeneca upgraded its New York listing last year and subsequently committed **US$50 billion** to American manufacturing and research facilities.\n\nDespite its growing US focus, the company has maintained that it intends to keep its headquarters in Cambridge and retain its London Stock Exchange listing.\n\nAny transaction would likely attract close political and regulatory scrutiny in Britain, reviving memories of Pfizer’s unsuccessful attempt to acquire AstraZeneca more than a decade ago.\n\nAstraZeneca employs around **10,000 people across five UK sites**, including major operations in Cambridge and Macclesfield.\n\nIts shares had risen around **13% over the previous year**, compared with a gain of **43%** for Bristol Myers Squibb."}